[1] Addison WR,Waiters KA,Wong WW,et al.Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.J Virol,2002,76:6356-6363.
[2] Idilman R,Cinar K,Seven G,et al.Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HbeAg-negative chronic hepatitis B patients.J Viral Hepat,2012,19:220-226.
[3] Fontana RJ.Side effects of long.term oral antiviral therapy for hepatitis B.Hepatology,2009,49:S185-S195.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).中华试验和临床传染病杂志:电子版,2015,9:570-589.
[5] Ishikawa T.Immunoregulation of hepatitis B virus infection- rationale and clinical application.Nagoya J Med Sci,2013,74:217。
[6] Seeger C,Mason WS.Hepatitis Bvirus biology.Microbiol Mo lBiol Rev,2000,64:51-68.
[7] 陈智.乙型肝炎病毒 cccDNA 研究现状.中华传染病杂志,2009,21:8-10.
[8] 郭亚兵,喻新民,冯筱榕,等.拉米夫定停药后慢性乙型肝炎病情加重3例报道.中华肝脏病杂志,2000,8:360.
[9] Hadziyannis SJ,Sevastianos V,Rapti I,et al.Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.Gastroenterology,2012,143:629-636.
[10] 陈合民,邵国辉.核苷和核苷酸类药物治疗慢性乙型肝炎停药标准的探讨.临床肝胆病杂志,2016,32:1283-1286. |
